CN101531613B - Aminopeptidase N inhibitor bestatin dino ester, synthesis and application thereof - Google Patents
Aminopeptidase N inhibitor bestatin dino ester, synthesis and application thereof Download PDFInfo
- Publication number
- CN101531613B CN101531613B CN2009100206554A CN200910020655A CN101531613B CN 101531613 B CN101531613 B CN 101531613B CN 2009100206554 A CN2009100206554 A CN 2009100206554A CN 200910020655 A CN200910020655 A CN 200910020655A CN 101531613 B CN101531613 B CN 101531613B
- Authority
- CN
- China
- Prior art keywords
- ubenimex
- ester
- enlightening
- prodrug
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides an intensive antitumor medicament, namely bestatin deanol ester, a preparation method and application thereof. The bestatin deanol ester not only can effectively inhibit ectopic expression of aminopeptidase N activity, but also greatly improve the water solubility of the parent drug bestatin of the bestatin deanol ester, has slow release effect, is more excellent than the parent drug bestatin either from healing effect or preparation, and has wide application. Particularly, the invention mainly relates to the following three aspects: (1) design and synthesis of the bestatin deanol ester; (2) N'N deanol which is a micromolecule fragment, can be connected with other medicaments containing carboxyl, improves the pharmacokinetic property of the medicaments, and improves water solubility; and (3) a method for synthesizing an ester substance to which the invention relates with wide application and mild condition.
Description
Technical field
The present invention relates to the prodrug of aminopeptidase N inhibitor Bestatin (ubenimex), the design of ubenimex enlightening promise ester, synthetic and possible medicinal use.Belong to technical field of pharmaceuticals.
Background technology
1. Aminopeptidase N (APN)
Aminopeptidase N (APN/CD13) is a kind of two shaped metal exopeptidases that depend on zine ion, is under the jurisdiction of M1 aminopeptidase extended familys.Its physiologic function is the degraded of participating in substrate N terminal amino acid.Under the normal condition, APN is extensive low expression level in tissues such as mammiferous kidney, small intestine and cns, participates in the physiological regulation of body.The research proof, Aminopeptidase N is a kind of multifunctional enzyme, and substrate is extensive, and it takes place in tumour, immunologic function is regulated, and virus infection and ease pain all play an important role.
(1) APN is at the tumor cell surface high level expression.This enzyme can make the staple degraded of extracellular matrix (ECM), has destroyed the natural cover for defense of body, promotes invasion by tumor cells, growth and transfer, and participates in the tumour neovascularity and generate, thereby required nutrient is provided for growth of tumor.(referring to Saiki, I.; Et al.Int.J.Cancer., 1993,54,137; Sato, Y.Biol.Pharm.Bull., 2004,772,776).
(2) APN has also participated in the inflammatory reaction that the T lymphocyte relies on simultaneously in granulocyte and lymphocytic cell surface great expression; Can also be expressed in the antigen presenting cell surface, degraded immunologic active material (like interleukin-8); The T cell that mhc II type (MHC-II) the Adhesion Antigen determinant of processing of participation antigen and cell surface relies on is to antigenic identification; Reduced the recognition capability of T cell; Weakened scavenger cell and NK cell identification and kill capability simultaneously, immunity of organisms is descended tumour cell.
(3) APN is as the acceptor on human corona virus HCoV-229E and TGE (TGEV) surface; In upper respiratory tract infection (as: SARS) and acute enteritis, play an important role, and its activity with enzyme of playing a role relevant (referring to Delmas, B.; Et al.Nature; 1992,357,417; Yeager, C.L.; Et al.Nature, 1992,357,420).
(4) APN participates in the process that the HIV virion gets into host cell.Research shows that the APN activity is higher than the healthy volunteer far away in patient's body of infected by HIV.When HIV-1 invasion host cell, the APN of high expression level can make the chemokine fMLP of HIV-1 auxiliary receptor CCR 5 desensitization through degraded, thereby reduces the natural immunity function of cell, and makes the CCR5 enhanced sensitivity, promotes virus to get into host cell.(referring to Shen W, Li B, et al.Blood, 2000,96 (8), 2887; Shipp MA, et al.Blood, 1993,82 (4), 1052)
(5) APN participates in the degraded of endogenous analgesic matter endorphin and enkephalin, thereby causes the excessive release of P material, causes pain.
(6) APN degraded II Angiotensin II, and the adjusting of participation body blood pressure (referring to Mitsui, T.; Et al.Biol.Pharm.Bull., 2004,27,768.)
2. ubenimex
It is glad that ubenimex has another name called hundred scholars, English Bestatin by name, Ubenimex, and chemistry is by name: nitrogen-[(2S, 3R)-3-amido-2-hydroxy-4-phenyl butyryl]-the L-leucine.(referring to H.Suda et al., ibid.100.Syntheses:eidem, ibid.600; R.Nishizawa et al., ibid.1983,36,695) the CAS number of registration is 58970-76-6.
Ubenimex is a kind of aminopeptidase N inhibitor, and these article can be used for raise immunity, is used for the assisting therapy of anticancer chemotherapy, radiotherapy, senile immunodeficiency etc., also can directly be used for tumour such as leukemic treatment.Its chemical structure is following:
The U.S. department of horse benzene
Comprise a primary amine groups and a carboxyl in the ubenimex structure, both can form inner salt, therefore are insoluble in various organic solvents, and water-soluble also relatively poor, bioavailability is low, metabolic stability is poor thereby cause, and has limited its use.
Summary of the invention
The present invention is directed to the deficiency of existing anticancer ancillary drug ubenimex aspect pharmacokinetic property, a kind of good water solubility, good drug efficacy, ubenimex enlightening promise ester that medicine stability is good are provided.
The present invention also provides the compound method and the application of above-mentioned ubenimex enlightening promise ester.
In order to improve the ubenimex pharmacokinetic property, improve water-solublely, the present invention transforms ubenimex, and a kind of ubenimex enlightening promise ester is provided, and its structural formula is following:
Contain a primary amine groups and a tertiary amine groups in this prodrug structure, both each can combine the hydrogenchloride of a part, thereby form bimolecular hydrochloride, water-soluble raising greatly, thereby applicable to multiple drug formulation.Make molecular structure more stable simultaneously.
Used term and definition implication is following:
Naphthene group is replacement or unsubstituted, saturated or undersaturated cyclic group, and it contains carbon atom and one or more heteroatoms.This ring can be monocycle or condensed ring, the ring system of bridged ring or volution.
THF: THF;
(Boc)
2O: tert-Butyl dicarbonate, structure is:
HOBt:N-hydroxy benzo tetrazole, structure is:
DCC: NSC 57182, structure is:
DMAP: to dimethylamino pyridine, structure is:
The compound method of ubenimex enlightening promise ester of the present invention, step is following:
(1) ubenimex with optical purity is a starting raw material, under the alkaline condition of pH=9-10, makes the reaction of ubenimex and tert-Butyl dicarbonate, and the primary amine groups of ubenimex is carried out the Boc protection, then,
(2) make solvent with anhydrous tetrahydro furan, under the katalysis of 0 ℃ of temperature and DCC, the ubenimex and the N-hydroxy benzo tetrazole of the product B oc of step (1) protection is condensed into active ester, then,
(3) go up step reaction product active ester and at room temperature reach under the katalysis of DMAP again, be reacted into ester with N ' N dimethylethanolamine, generate the prodrug of Boc protection, the mol ratio of said active ester and N ' N dimethylethanolamine is 1: 3.
(4) prodrug that the Boc that step (3) is obtained protects is taken off the Boc blocking group in the saturated ethyl acetate solution of hydrogenchloride, get target compound.
Wherein, it is following that step (3) becomes the ester reaction formula:
R1, R2 are various types of substituting groups, like fat group or aromatic group, can be that chain also can be a cyclic substituents.
Preferred consumption is following:
In the step (1), ubenimex is 1: 1.1 with the molar weight ratio of tert-Butyl dicarbonate,
In the step (2), N-hydroxy benzo tetrazole is 1: 1.08 with the molar weight ratio of ubenimex, and NSC 57182 is 1: 1.1 with the molar weight ratio of ubenimex.
In the step (3), to the dimethylamino pyridine catalytic amount 0.2 times of ubenimex molar weight.
Below being preferred, is a concrete route of synthetic its prodrug of starting raw material with the ubenimex of optical purity:
Contain amido, two active groups of hydroxyl in the ubenimex structure, carry out on this basis amido Boc protection, carboxyl activation, esterification, take off these four basic steps of amido Boc protection, N ' N dimethylethanolamine and carboxyl are connected to ester.Both protect carboxyl, strengthened the metabolic stability of medicine.Meanwhile introduce a tertiary amine groups again, thus can with two molecule hydrogenchloride salifies, increased the water-soluble of medicine, improved its pharmacokinetic property.One-tenth ester method of the present invention has the advantage that does not influence the intramolecularly reactive group.
The present invention designs and has synthesized a ubenimex enlightening promise ester with brand new.Experiment in vitro shows that it presses down enzymic activity significantly, and can become one is the novel prodrugs of skeleton with the ubenimex.This method also is applicable to any design that contains the prodrug of free carboxy medicine.Simultaneously, the synthetic used one-tenth ester method of this prodrug also has novelty, be applicable to that most carboxyls react with the ester that becomes of alcohol, and reaction conditions is gentle, is particularly useful for the one-tenth ester reaction to thermally labile acid.
See that from reaction result this ubenimex enlightening promise ester finally is that the form with two molecule hydrochlorides exists, have extremely strong water-solublely, help the preparation of solution in the process of active testing and the design of pharmaceutical dosage form.
Next step will carry out external antitumor cell experiment and vitro stability experiment the ubenimex enlightening promise ester that obtains.
In sum, these invention major technique characteristics comprise following three parts:
(1) this natural radioactivity small molecules and ubenimex that contains the tertiary amine structure forms ester class prodrug with N ' N dimethylethanolamine, thereby improves its stability and pharmacokinetics character.
(2) simultaneously, N ' N dimethylethanolamine also can be used for connecting the compound that other comprise free carboxy, improves that it is water-soluble.
(3) used a kind of one-tenth ester method of novelty in this building-up process, the advantage of these one-tenth ester means is can not have influence on other reactive group in the drug molecule, and reaction conditions is gentle, and is widely applicable.
The present invention becomes ester with ubenimex with N ' N dimethylethanolamine, when increasing medicine stability, has improved greatly that it is water-soluble, has well improved its waistband kinetic property, has improved bioavailability, and meta-bolites also has no side effect.Draw inferences about other cases from one instance, any have carboxyl, a water-soluble relatively poor medicine, all can form a kind of structure of ester with N ' N dimethylethanolamine, again with various organic or inorganics acid salifies, increases that it is water-soluble.
N ' N dimethylethanolamine, English N by name, N-dimethyl ethanolamine or Deanol; Be a kind of natural active matter that exists at nature, it can increase the intravital choline amount of people, thus with memory; Study, thinking has confidential relation, (referring to Alfredo Gragnan; Etc.iAesth.Plast.Surg.2007,31,711-718; AlfredoGragnani, etc.Aesth.Plast.Surg.2008,32,406.) it takes as a kind of medicine in American-European countries, is used for the improvement of crease-resistant and brain function, and toxic side effect is little.Simultaneously, how tumour patient can follow various miseries during treating, thereby makes tumour patient have the fidgets, and as the precursor of choline, N ' N dimethylethanolamine can effectively improve this dysphoric undesirable condition.Therefore the present invention selects N ' N dimethylethanolamine to become ester with ubenimex, this method can not make various sensitive groups in the drug molecule as: amido, hydroxyl, sulfydryl etc. are affected, and the reaction conditions gentleness, have general suitability.
Press down the enzymic activity experiment in the external and body of ubenimex enlightening promise ester of the present invention:
1. external inhibition activity experiment to Aminopeptidase N:
Experimental principle: APN suppresses active test description in Lejczak, and .Biochemistry such as B are in 1989,28,3549.Substrate is L-leucyl-p-N-methyl-p-nitroaniline, and it can be degraded by APN, be created on the p-N-methyl-p-nitroaniline that 405nm has absorption, and the size of the concentration of p-N-methyl-p-nitroaniline and enzymic activity is proportionate.Confirm the content of p-N-methyl-p-nitroaniline through the optical density that detects 405nm place, can confirm the activity of Aminopeptidase N, thereby reflect the big or small materials and methods of suppressor factor indirectly enzymic activity inhibition degree:
Aminopeptidase N and substrate L-leucyl-p-N-methyl-p-nitroaniline are all available from Sigma company
The preparation of solution:
Damping fluid, preparation pH7.2, the 50mM phosphate buffered saline buffer, room temperature is placed subsequent use.
Aminopeptidase N is dissolved in the solution that is made into 0.2mg/mL in the damping fluid;
Substrate is dissolved in and is made into 0.5mg/mL solution among the DMSO, and each solution refrigerator is placed subsequent use.
Amino-peptidase activity is analyzed:
Add above-mentioned Aminopeptidase N solution 10 μ L in 96 orifice plates, substrate solution is supplied 200 μ L with damping fluid., under 35 ℃, in shaking table, rocked 30 minutes, utilize ELIASA to measure absorption value in the 405nm wavelength.
Pressing down enzyme detects:
Add above-mentioned Aminopeptidase N solution 10 μ l in 96 orifice plates respectively, substrate 5 μ l, the compound 40 μ l of different gradient concentrations; Compound always has 6 concentration gradients, is respectively 130 μ g/ml, 32 μ g/ml; 8 μ g/ml, 2 μ g/ml, 0.5 μ g/ml and 0.125 μ g/ml.Supply 200 μ L with 175ml phosphate buffered saline buffer (pH7.2) at last.100% group does not contain suppressor factor.Blank control group replaces organized enzyme with the enzyme of inactivation, all supplies 200 μ L with damping fluid.Under 35 ℃, in shaking table, rocked 30 minutes, utilize ELIASA again, measure each hole absorption value in the 405nm wavelength.Calculate inhibiting rate according to following formula at last:
Inhibiting rate=(100% optical density-compound optical density)/(100% optical density-blank optical density)
According to compound concentrations and corresponding inhibition ratio, utilize Origin7.5 software match beneficial effect curve, calculate the IC of prodrug
50Value.
Table 1: the external enzyme experimental result that presses down
| IC 50(μ mol/ml) value | |
| Ubenimex enlightening promise ester | 0.06 |
| Ubenimex | 0.003 |
Annotate: numerical value is the MV of three experiments in the table.Enzymic activity experiment shows, the prodrug inhibitory enzyme activity is less than parent drug, ubenimex.
2. vitro inhibition tumor cell viability.
Experimental principle and step:
Thiazolyl blue; Be called for short MTT; But permeate through cell membranes gets in the cell, and the amber desaturase in the viable cell plastosome can make exogenous MTT be reduced to be insoluble in the hepatic Formazan crystallization of water and be deposited in the cell, and crystallisate can be dissolved by DMSO 99.8MIN. (DMSO); Measure its absorbance value with enzyme-linked immunosorbent assay instrument in the 570nm wavelength, can reflect cell quantity indirectly.The amount that the MTT crystallisate forms is directly proportional with viable count, and is also proportional with cell viability.
The test cell is human lung carcinoma cell (A549), clear cell carcinoma of ovary cell (ES-2), and human leukemia cell (HL-60) adds 10% foetal calf serum with the RPMI1640 substratum and cultivates.
Step:
(1) shop 96 orifice plates, every hole 50ul, 5000 cells (A549, ES-2 are 5000, and HL-60 is 50000);
(2) behind the bed board 4h, add the substratum that 50ul contains the different concns compound in the hole, make that the compound final concentration is respectively in the hole: prodrug is 200,100,50,25,12.5ug/ml; Bestatin is 800,600,400,200,100ug/ml, and each concentration is established three multiple holes, does not make Blank when not adding the hole reading of cell, and the compound blank is made in the solvent hole;
(3) behind the adding compound 48h, Xiang Kongzhong adds 0.5% MTT, every hole 10ul;
(4) behind the adding MTT 4h, 2500rpm, 30min is centrifugal, throws plate and abandons substratum in the hole, adds DMSO, the 100ul/ hole;
(5) ELIASA is surveyed 570nm place absorbance, 630nm wavelength for referencial use
Inhibiting rate=(compound blank control group-test group)/compound blank control group * 100% experimental result:
Table 2: prodrug is to A549 cell inhibiting result
| Inhibiting |
12.5ug/ml | 25ug/ml | 50ug/ml | 100ug/ml | 200ug/ml |
| LYP | 4.079277 | 7.056127 | 14.88414 | 32.19397 | 50.16533 |
Table 3: prodrug is to ES-2 cell inhibiting result
| Inhibiting |
12.5ug/ml | 25ug/ml | 50ug/ml | 100ug/ml | 200ug/ml |
| LYP | 6.397573 | 26.9612 | 0.990101 | 50.03816 | 61.91936 |
Table 4: prodrug is to HL60 cell inhibiting result
| Inhibiting |
50ug/ml | 100ug/ml | 150ug/ml | 200ug/ml |
| LYP | 47.65403 | 40.76252 | 32.55137 | 15.54254 |
Table 5: prodrug, ubenimex are to the median effective dose of three kinds of tumour cells
Can find out that from above result ubenimex enlightening promise ester has better effect aspect these three kinds of tumour cells of inhibition.Median effective dose will be much smaller than parent drug---ubenimex.This result's safety will more be higher than the enzymic activity experiment.
3. experiment in the mouse body
This experiment has selected for use mouse to experimentize, and mouse is inoculated H22 (human liver cancer cell) solid tumor, carries out activity experiment respectively with ubenimex enlightening promise ester and ubenimex, and last is the activity that standard is judged compound with the tumour inhibiting rate.
Ubenimex enlightening promise ester has selected three dosages to be respectively 100mg/kg; 50mg/kg and 25mg/kg, ubenimex concentration is 100mg/kg, shown in experimental result Fig. 1; From then on can find out in the histogram; Prodrug is at 00mg/kg, and the tumour inhibiting rate under three dosage of 50mg/kg and 25mg/kg is respectively 35%, 16% and 13%.
Ubenimex enlightening promise ester and ubenimex specific activity are seen Fig. 2, and under 100mg/kg dosage, the inhibiting rate of ubenimex enlightening promise ester and ubenimex is respectively 35% and 3%, and the activity of ubenimex enlightening promise ester will be apparently higher than ubenimex.
4. mouse interior medicine dynamics test
Get Kunming kind healthy mice, be divided into 2 groups at random, the 1st group is the ubenimex group, and the 2nd group is the prodrug group, 3 of the parallel settings of each time point.Tail vein injection ubenimex and prodrug, ubenimex dosage 100mg/kg, prodrug dosage are then by waiting administration of mole ubenimex dosage.Mouse fasting 12h before the administration freely drinks water, and gets blood respectively at 5min, 15min, 30min, 45min, 1,2,4,6,8,12,24h after (0h), the administration before the administration in the eyeground vein clump, adds in the centrifuge tube of heparin sodium rinse.Accurate absorption blood plasma 200 μ l place the 1.5ml centrifuge tube, the accurate acetonitrile solution 50 μ l that contain 25% perchloric acid that add, and the vortex vibration, centrifugal (15000rpm) 20min gets supernatant sample introduction 25 μ l HPLC mensuration Plasma Concentration respectively.
The average drug-time curve of ubenimex and prodrug is seen Fig. 3,4,5,6.
Calculate its main moment parameter, the result sees table 6, table 7.Can calculate by TG-AUC AUC0-t (μ g/ml*h) value; The mouse tail vein prodrug is 112.1% in the relative bioavailability of ubenimex; The mouse oral prodrugs is 96.68% in the relative bioavailability of ubenimex; In statistical analysis tail vein injection and oral administration group, the AUC0-t of prodrug and ubenimex there are no significant difference (P＞0.05) is explained prodrug and ubenimex bioequivalence; Residence time (MRT 0-t) and transformation period (T1/2) in the body of comparative drug; Prodrug and ubenimex T1/2 and MRT 0-t have statistical significance (P＜0.05), and promptly prodrug group T1/2 and MRT 0-t all have increase than the ubenimex group, after prodrug is processed in this explanation; Owing to improved water-soluble; Make medicine have suitable profit partition ratio, it is long to keep the effective plasma concns time, can prolong the transformation period of ubenimex.
The main moment parameter of table 6. mouse tail vein injection administration ubenimex and prodrug
Main moment parameter behind table 7. mouse oral administration ubenimex and the prodrug
5. inside and outside stability experiment:
Ubenimex enlightening promise ester is stable in the HCl of water, 0.1mol/L solution; In the PBS of pH7.4 solution, degrade, mainly contain two degraded products, can confirm as ubenimex according to RT for one, another is a N ' N dimethylethanolamine.
Table 8 vitro stability experiment (pH=7.4PBS)
| Time | Ubenimex enlightening promise ester (degradation amount) | Ubenimex (peak area/concentration) | N ' N dimethylethanolamine (peak area) |
| 0min | 0 | 277821(0.91mg/ml) | 110856 |
| 15min | 18.97％ | 351148(1.15mg/ml) | 265968 |
| 30min | 33.49％ | 414490(1.36mg/ml) | 342049 |
| 1h | 65.21％ | 511193(1.67mg/ml) | 458371 |
| 2h | 79.5％ | 571432(1.87mg/ml) | 448440 |
| 4h | 91.3％ | 758511(2.48mg/ml) | 592127 |
| 8h | 96.92％ | 913148(2.99mg/ml) | 447457 |
| 12h | 98.62％ | 1011371(3.31mg/ml) | 288689 |
| 24h | 98.86％ | 1195366(3.91mg/ml) | 126849 |
Can find out from showing various data,, play antitumor action because pH value of human body about 7.2-7.3, also can slowly be degraded in vivo so can predict the ubenimex prodrug, thereby discharge the parent drug ubenimex.Even be not degraded, because above-mentioned activity experiment proves that ubenimex prodrug activity is superior to the parent drug ubenimex, so ubenimex prodrug itself has good antineoplastic activity too.
The application of aforesaid ubenimex enlightening promise ester in preparation medicine for treating tumor thing.
The preparation purposes
Preferably, ubenimex enlightening promise ester is used to prepare injection.Also can be prepared into and be suitable for oral tablet or dripping pill.
Ubenimex suppresses all to be used for oral administration all the time, and for the cancer patients, particularly Advanced Carcinoma Patient is unfavorable for oral administration, and the bioavailability of oral administration is low, and document shows that ubenimex is to discharge in body with the form of former medicine more than 85%.And ubenimex enlightening promise ester belongs to two molecule hydrochlorides, water-soluble height, thus can process injection; Like chloride injection agent, glucose injection agent or the like; Can improve the bioavailability of parent drug so greatly, and because prodrug has slow-release function, thereby the parent drug residence time in vivo can be prolonged; Improve drug effect, reduce administration number of times.
Description of drawings
Fig. 1 is the active figure of ubenimex enlightening promise ester of the present invention, and X-coordinate is a ubenimex enlightening promise ester concentration (mg/ml), and ordinate zou is tumour inhibiting rate (%).
Fig. 2 is the active comparison diagram of ubenimex enlightening promise ester of the present invention and ubenimex, and X-coordinate is inhibiting rate (%), and prodrug and the ubenimex inhibiting rate under 50mg/ml concentration is respectively 35% and 3%.
Fig. 3 is the average drug-time curve of mouse tail vein injection ubenimex
Fig. 4 is the average drug-time curve of mouse prodrug tail vein injection ubenimex
Fig. 5 is the average drug-time curve behind the mouse oral administration ubenimex
Fig. 6 is the average drug-time curve of mouse oral administration prodrug group ubenimex
Embodiment
Below in conjunction with embodiment the present invention is further specified, but be not limited thereto.
Embodiment 1:
Antitumor drug with structure, ubenimex enlightening promise ester:
The route of synthetic ubenimex enlightening promise ester:
Ubenimex enlightening promise ester compound method, step is following:
(1) ubenimex with optical purity is a starting raw material, under the alkaline condition of pH=9-10, makes ubenimex and tert-Butyl dicarbonate reaction (the tert-Butyl dicarbonate molar weight is 1.1 times of ubenimex), and the primary amine groups of ubenimex is carried out the Boc protection,
(2) make solvent with anhydrous tetrahydro furan; Under the katalysis of 0 ℃ of temperature and NSC 57182 (DCC) (the DCC molar weight is 1.1 times of ubenimex); The ubenimex and the HOBt (molar weight is 1.08 times of ubenimex) of the product B oc of step (1) protection are condensed into active ester
(3) going up step reflection its lytic activity ester at room temperature reaches under the katalysis to dimethylamino pyridine (DMAP) (the DMAP molar weight is 0.2 times of ubenimex) again; Be reacted into ester with N ' N dimethylethanolamine; Generate the prodrug of Boc protection, the mol ratio of said active ester and N ' N dimethylethanolamine is 1: 3.
(4) prodrug that the Boc that step (3) is obtained protects is taken off the Boc blocking group in the saturated ethyl acetate solution of hydrogenchloride, get target compound.
Embodiment 2:
Take by weighing sodium-chlor by the recipe quantity precision, add the water for injection dissolving of recipe quantity 70%, by volume add 1% gac; Stir, filter, HCl regulates pH 5; The ubenimex enlightening promise ester that adds recipe quantity embodiment 1, stirring and dissolving, water for injection is to 1000ml; Filter, embedding is in the 2ml ampoule, and sterilize promptly got in 30 minutes.
Embodiment 3:
Take by weighing glucose by the recipe quantity precision, add the water for injection dissolving of recipe quantity 70%, by volume add 1% gac; Stir, filter, HCl regulates pH 5; The ubenimex enlightening promise ester that adds recipe quantity embodiment 1, stirring and dissolving, water for injection is to 1000ml; Filter, embedding is in the 2ml ampoule, and sterilize promptly got in 30 minutes.
Embodiment 4:
Take by weighing the ubenimex enlightening promise ester of embodiment 1 by the recipe quantity precision; In medicine: PEG6000: water: glycerine was in 1: 1.8: 0.4: 0.4 ratio mixing; Be incubated in the system of the dripping device of (90 ± 2) ℃, use the drip inner/outer diameter to splash in the quench liquid of temperature as room temperature so that dripping of (10 ± 2) D/min is fast as the dropper of 2.5/3.5 (mm).
Embodiment 4:
Take by weighing the ubenimex enlightening promise ester of embodiment 1 by the recipe quantity precision; Add the Microcrystalline Cellulose thorough mixing in 20% ratio; Add 5% cross-linked polyvinylpyrrolidone and 0.3% micropowder silica gel then, carry out direct powder compression behind the mixing, the hardness of control tablet is 3～4kgcm-2.Made dispersible tablet can be in 3min disintegration and all sieving fully through No. 2, meet that " Chinese pharmacopoeia is to the requirement of burst.
Embodiment 5:
Take by weighing the ubenimex enlightening promise ester of embodiment 1 by the recipe quantity precision, with HPMC, the IV vinyl resin prepares the sheet heart as main binder, and the hard-hearted degree of sheet reaches more than the 0.5MPa, about disintegration 10min, friability＜1% is unilateral level and smooth.Film-coated optimum process parameter: the Opadry consumption of dressing is 5%, discharge rate 400g/min, rotating speed 15r/min.
Claims (6)
1. the antitumor drug that has structure, ubenimex enlightening promise ester:
2. the preparation method of ubenimex enlightening promise ester as claimed in claim 1 is characterized in that this method is: introduce this natural radioactivity small molecules of N ' N dimethylethanolamine on the carboxyl, its structural formula is following:
The route of synthetic ubenimex enlightening promise ester:
The compound method of ubenimex enlightening promise ester, step is following:
(1) ubenimex with optical purity is a starting raw material, under the alkaline condition of pH=9-10, makes the reaction of ubenimex and tert-Butyl dicarbonate, and the primary amine groups of ubenimex is carried out the Boc protection,
(2) make solvent with anhydrous tetrahydro furan, under the katalysis of 0 ℃ of temperature and DCC, the ubenimex and the N-hydroxy benzo triazole of the product B oc of step (1) protection be condensed into active ester,
(3) go up step reaction product active ester and at room temperature reach under the katalysis of DMAP again, be reacted into ester with N ' N dimethylethanolamine, generate the prodrug of Boc protection, the mol ratio of said active ester and N ' N dimethylethanolamine is 1: 3;
(4) prodrug that the Boc that step (3) is obtained protects is taken off the Boc blocking group in the saturated ethyl acetate solution of hydrogenchloride, get target compound.
3. the preparation method of ubenimex enlightening promise ester as claimed in claim 2 is characterized in that in the step (1), and ubenimex is 1: 11 with the molar weight ratio of tert-Butyl dicarbonate.
4. the preparation method of ubenimex enlightening promise ester as claimed in claim 2 is characterized in that in the step (2), and the N-hydroxy benzo triazole is 1: 1.08 with the molar weight ratio of ubenimex, and NSC 57182 is 1: 1.1 with the molar weight ratio of ubenimex.
5. the preparation method of ubenimex enlightening promise ester as claimed in claim 2 is characterized in that in the step (3), is 0.2 times of ubenimex molar weight to the dimethylamino pyridine catalytic amount.
6. the application of ubenimex enlightening promise ester as claimed in claim 1 in preparation medicine for treating tumor thing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100206554A CN101531613B (en) | 2009-04-16 | 2009-04-16 | Aminopeptidase N inhibitor bestatin dino ester, synthesis and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100206554A CN101531613B (en) | 2009-04-16 | 2009-04-16 | Aminopeptidase N inhibitor bestatin dino ester, synthesis and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101531613A CN101531613A (en) | 2009-09-16 |
| CN101531613B true CN101531613B (en) | 2012-01-18 |
Family
ID=41102495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009100206554A Expired - Fee Related CN101531613B (en) | 2009-04-16 | 2009-04-16 | Aminopeptidase N inhibitor bestatin dino ester, synthesis and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101531613B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101665449B (en) * | 2009-09-24 | 2012-12-12 | 山东大学 | Water-soluble prodrug of tamibarotene, and preparation method and applications thereof |
| CN103588713B (en) * | 2013-06-07 | 2014-09-17 | 潍坊博创国际生物医药研究院 | Multi-target ubenimex prodrug derivative, as well as preparation method and application thereof |
| CN108977498B (en) * | 2018-06-19 | 2022-09-20 | 潍坊医学院 | Method for determining enzyme inhibition activity of aminopeptidase N inhibitor and application thereof |
| CN109846873B (en) * | 2018-12-18 | 2022-03-18 | 江西润泽药业有限公司 | Anti-tumor medicine composition |
| CN109646429B (en) * | 2018-12-21 | 2021-08-10 | 江西润泽药业有限公司 | Solid dosage form containing ubenimex prodrug derivative and preparation method thereof |
| CN113876784B (en) * | 2021-09-27 | 2023-07-21 | 潍坊博创国际生物医药研究院 | Novel application of boro-leucine compound |
| CN114349816A (en) * | 2021-11-30 | 2022-04-15 | 青岛博创生物科学研究院 | Small molecule coupling molecule based on aminopeptidase N/CD13 and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4189604A (en) * | 1975-07-22 | 1980-02-19 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Bestatin |
| WO2004014879A1 (en) * | 2002-08-08 | 2004-02-19 | Fujisawa Pharmaceutical Co., Ltd. | New process |
-
2009
- 2009-04-16 CN CN2009100206554A patent/CN101531613B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4189604A (en) * | 1975-07-22 | 1980-02-19 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Bestatin |
| WO2004014879A1 (en) * | 2002-08-08 | 2004-02-19 | Fujisawa Pharmaceutical Co., Ltd. | New process |
Non-Patent Citations (5)
| Title |
|---|
| Fei Wu et al..Synthesis,in vitro inhibitory activity towards COX-2 and haemolytic activity of derivatives of Esculentoside A.《Bioorganic & * |
| FeiWuetal..Synthesis in vitro inhibitory activity towards COX-2 and haemolytic activity of derivatives of Esculentoside A.《Bioorganic & Medicinal Chemistry》.2007 |
| Medicinal Chemistry》.2007,(第17期),第6430-6433页. * |
| Yepeng Luan et al..The Review of the Synthesis os Bestatin, an Effective Inhibitor of Aminopeptidase N.《Mini-Reviews in Organic Chemistry》.2008,第5卷(第2期),第134-140页. * |
| YepengLuanetal..TheReviewoftheSynthesisosBestatin an Effective Inhibitor of Aminopeptidase N.《Mini-Reviews in Organic Chemistry》.2008 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101531613A (en) | 2009-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101531613B (en) | Aminopeptidase N inhibitor bestatin dino ester, synthesis and application thereof | |
| US10952997B2 (en) | Methods for the administration of certain VMAT2 inhibitors | |
| CN101500572B (en) | Solid compositions comprising tadalafil and at least one carrier | |
| US10993941B2 (en) | Methods for the administration of certain VMAT2 inhibitors | |
| TWI233809B (en) | Dosage forms for providing effective reboxetine therapy with once-a-day dosing | |
| CN105263498A (en) | Cenicriviroc compositions and methods of making and using the same | |
| CN107530348A (en) | A kind of pharmaceutical composition containing jak kinase inhibitor or its officinal salt | |
| CN102946869A (en) | Immediate release formulations and dosage forms of gamma-hydroxybutyrate | |
| CN108358917B (en) | Imidazo [1,2-a ] pyridine-3-amide compound containing basic fused ring segment and preparation method thereof | |
| CN101544572A (en) | Ambroxol derivative and method for preparing same | |
| CN101869633A (en) | Enteric-coated medicament combination containing epigallocatechin gallate | |
| WO2023200671A1 (en) | Tryptamine analogues | |
| CN102731396B (en) | Polyamine naphthalimide compounds and application of same in preparation of pharmaceutical preparation | |
| CN105582546B (en) | A kind of Entecavir phosphatide complexes and the compound enteric-coated tablet of diammonium glycyrrhizinate | |
| CN103284975B (en) | Metformin hydrochloride enteric capsule and preparation method thereof | |
| CN102319227A (en) | Lomerizine hydrochloride osmotic pump tablet and preparation method thereof | |
| US6268368B1 (en) | Anionic exchange polymer complexes of buspirone | |
| CN110917197A (en) | Pharmaceutical composition of tenofovir disoproxil fumarate and emtricitabine and preparation method thereof | |
| CN100551373C (en) | The buspirone hydrochloride slow/controlled release pellet | |
| EP2050456A1 (en) | Tablet | |
| TW202400146A (en) | Use of combination of meropenem and vaborbactam | |
| CN109305979A (en) | 4- dimethylaminobenzaldehyde is preparing the application in NA inhibitor | |
| CN107118176B (en) | N-(5- benzyl thiazol-2-yl) morpholinyl amide and its medical usage | |
| CN107011337B (en) | N- [5- (1,2,4- triazol-1-yl) thiazol-2-yl] piperidyl amide and its medical usage | |
| CN1245980C (en) | Oral slow-release and controlled-release preparation for curing depression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120118 Termination date: 20120416 |